New cocktail of drugs takes on tough lung cancers in Never-Smokers

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to a standard three-drug chemotherapy regimen (carboplatin, pemetrexed, and bevacizumab) helps people with advanced non-squamous lung cancer live longer without their disease worsening. The study enrolls 107 patients whose tumors either have a specific EGFR mutation or who have never smoked and lack certain other mutations. Researchers are comparing the combination with and without atezolizumab to see if the immune-boosting agent improves outcomes.